1. Home
  2. MFG vs VRTX Comparison

MFG vs VRTX Comparison

Compare MFG & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mizuho Financial Group Inc. Sponosred ADR (Japan)

MFG

Mizuho Financial Group Inc. Sponosred ADR (Japan)

SELL

Current Price

$9.83

Market Cap

113.5B

Sector

Finance

ML Signal

SELL

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

SELL

Current Price

$534.06

Market Cap

135.6B

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
MFG
VRTX
Founded
2003
1989
Country
Japan
United States
Employees
N/A
N/A
Industry
Major Banks
EDP Services
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
113.5B
135.6B
IPO Year
2005
2006

Fundamental Metrics

Financial Performance
Metric
MFG
VRTX
Price
$9.83
$534.06
Analyst Decision
Buy
Buy
Analyst Count
2
32
Target Price
$11.64
★ $595.36
AVG Volume (30 Days)
★ 4.5M
1.3M
Earning Date
11-13-2026
11-02-2026
Dividend Yield
★ 0.72%
N/A
EPS Growth
N/A
★ 836.54
EPS
N/A
★ 10.90
Revenue
N/A
★ $2,488,652,000.00
Revenue This Year
$104.46
$10.46
Revenue Next Year
$12.54
$10.53
P/E Ratio
★ $16.74
$49.01
Revenue Growth
N/A
★ 46.20
52 Week Low
$6.45
$412.27
52 Week High
$11.49
$568.67

Technical Indicators

Market Signals
Indicator
MFG
VRTX
Relative Strength Index (RSI) 44.67 49.75
Support Level $9.60 $493.75
Resistance Level $9.93 $536.58
Average True Range (ATR) 0.21 16.14
MACD 0.08 -1.47
Stochastic Oscillator 52.12 14.27

Price Performance

Historical Comparison
MFG
VRTX

About MFG Mizuho Financial Group Inc. Sponosred ADR (Japan)

Mizuho Financial Group is roughly tied with megabank peer Sumitomo Mitsui Financial Group for the status as Japan's second-largest bank after Mitsubishi UFJ Financial Group. In Japan, Mizuho has more of a corporate focus than SMFG, which has a larger retail business. Its overseas weighting is slightly smaller than that of MUFG. Mizuho expanded in recent years beyond its traditional Japanese borrowers, mainly through its core banking and securities units, focusing on the financing needs of global multinational corporations.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Share on Social Networks: